Are you over 18 and want to see adult content?
More Annotations
A complete backup of goodfoodjobs.com
Are you over 18 and want to see adult content?
A complete backup of cheapcialiswithprescription.com
Are you over 18 and want to see adult content?
A complete backup of chelseamichamber.org
Are you over 18 and want to see adult content?
A complete backup of fiercevaccines.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://gramotey.com
Are you over 18 and want to see adult content?
A complete backup of https://fdnyfoundation.org
Are you over 18 and want to see adult content?
A complete backup of https://trackmytruck.us
Are you over 18 and want to see adult content?
A complete backup of https://inwerk-bueromoebel.de
Are you over 18 and want to see adult content?
A complete backup of https://r20.rs6.net
Are you over 18 and want to see adult content?
A complete backup of https://whatsinblue.org
Are you over 18 and want to see adult content?
A complete backup of https://pokeworks.com
Are you over 18 and want to see adult content?
A complete backup of https://berneroberlaender.ch
Are you over 18 and want to see adult content?
A complete backup of https://mbr.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://shinanorailway.co.jp
Are you over 18 and want to see adult content?
A complete backup of https://wauwatosa.net
Are you over 18 and want to see adult content?
Text
Information.
HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 1 INDICATIONS AND USAGE 1.1 Rheumatoid Arthritis RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA SAFELY … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) BLEPHAMIDE ® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile Full Prescribing Information. BOTOX ® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use Full PrescribingInformation.
HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 1 INDICATIONS AND USAGE 1.1 Rheumatoid Arthritis RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA SAFELY … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. HIGHLIGHTS OF PRESCRIBING INFORMATION … HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNTHROID® safely and effectively. See full prescribing information HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information. For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. HIGHLIGHTS OF PRESCRIBING INFORMATION … 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICALSTUDIES
ABBVIE™ PEG
The AbbVie PEG is a percutaneous endoscopic gastrostomy (PEG, or gastric) tube, either 15 FR or 20 FR and 35 cm in length. The kit includes the following (Fig. HIGHLIGHTS OF PRESCRIBING INFORMATION • ORGANIC ANION pulmonary embolism). Estrogen and progestin combinations, including the estradiol/norethindrone acetate component of ORIAHNN, MEDICATION GUIDE HUMIRA The needle cover for the HUMIRA Pen 40 mg/0.8 mL, HUMIRA 40 mg/0.8 mL prefilled syringe, HUMIRA 20 mg/0.4 mL prefilled syringe, and HUMIRA 10 mg/0.2 mL prefilled HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. MEDICATION GUIDE ANDROGEL (AN DROW JEL) CIII MEDICATION GUIDE ANDROGEL® (AN DROW JEL) CIII (testosterone gel) 1% for topical use What is the most important information I should know about ANDROGEL 1%? 1.ANDROGEL 1% can transfer from your body to others including, children and GENGRAF ORAL SOLUTION (CYCLOSPORINE ORAL SOLUTION, USP DESCRIPTION Gengraf®Oral Solution (cyclosporine oral solution, USP ) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment. Cyclosporine, the active principle in Gengraf®Oral Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. INSTRUCTIONS FOR USE ABBVIE SNUG VEST INSTRUCTIONS FOR USE AbbVie Snug Vest For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Snug Vest.For questions or problems, refer to these Instructions for Use or call support toll free at 1- RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) BLEPHAMIDE ® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile Full Prescribing Information. BOTOX ® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use Full PrescribingInformation.
HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 1 INDICATIONS AND USAGE 1.1 Rheumatoid Arthritis RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION • ORGANIC ANION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORIAHNNsafely and effectively. See full prescribing information for MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) BLEPHAMIDE ® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile Full Prescribing Information. BOTOX ® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use Full PrescribingInformation.
HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 1 INDICATIONS AND USAGE 1.1 Rheumatoid Arthritis RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION • ORGANIC ANION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORIAHNNsafely and effectively. See full prescribing information for MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. HIGHLIGHTS OF PRESCRIBING INFORMATION … HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNTHROID® safely and effectively. See full prescribing information HIGHLIGHTS OF PRESCRIBING INFORMATION … 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICALSTUDIES
HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information. For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. HIGHLIGHTS OF PRESCRIBING INFORMATION • ORGANIC ANION pulmonary embolism). Estrogen and progestin combinations, including the estradiol/norethindrone acetate component of ORIAHNN,ABBVIE™ PEG
The AbbVie PEG is a percutaneous endoscopic gastrostomy (PEG, or gastric) tube, either 15 FR or 20 FR and 35 cm in length. The kit includes the following (Fig. MEDICATION GUIDE ANDROGEL (AN DROW JEL) CIII MEDICATION GUIDE ANDROGEL® (AN DROW JEL) CIII (testosterone gel) 1% for topical use What is the most important information I should know about ANDROGEL 1%? 1.ANDROGEL 1% can transfer from your body to others including, children and GENGRAF ORAL SOLUTION (CYCLOSPORINE ORAL SOLUTION, USP DESCRIPTION Gengraf®Oral Solution (cyclosporine oral solution, USP ) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment. Cyclosporine, the active principle in Gengraf®Oral Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. INSTRUCTIONS FOR USE ABBVIE SNUG VEST INSTRUCTIONS FOR USE AbbVie Snug Vest For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Snug Vest.For questions or problems, refer to these Instructions for Use or call support toll free at 1- RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) BLEPHAMIDE ® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile Full Prescribing Information. BOTOX ® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use Full PrescribingInformation.
HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 1 INDICATIONS AND USAGE 1.1 Rheumatoid Arthritis RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION • ORGANIC ANION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORIAHNNsafely and effectively. See full prescribing information for MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) BLEPHAMIDE ® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile Full Prescribing Information. BOTOX ® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use Full PrescribingInformation.
HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 1 INDICATIONS AND USAGE 1.1 Rheumatoid Arthritis RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION • ORGANIC ANION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORIAHNNsafely and effectively. See full prescribing information for MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. HIGHLIGHTS OF PRESCRIBING INFORMATION … HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNTHROID® safely and effectively. See full prescribing information HIGHLIGHTS OF PRESCRIBING INFORMATION … 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICALSTUDIES
HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information. For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. HIGHLIGHTS OF PRESCRIBING INFORMATION • ORGANIC ANION pulmonary embolism). Estrogen and progestin combinations, including the estradiol/norethindrone acetate component of ORIAHNN,ABBVIE™ PEG
The AbbVie PEG is a percutaneous endoscopic gastrostomy (PEG, or gastric) tube, either 15 FR or 20 FR and 35 cm in length. The kit includes the following (Fig. MEDICATION GUIDE ANDROGEL (AN DROW JEL) CIII MEDICATION GUIDE ANDROGEL® (AN DROW JEL) CIII (testosterone gel) 1% for topical use What is the most important information I should know about ANDROGEL 1%? 1.ANDROGEL 1% can transfer from your body to others including, children and GENGRAF ORAL SOLUTION (CYCLOSPORINE ORAL SOLUTION, USP DESCRIPTION Gengraf®Oral Solution (cyclosporine oral solution, USP ) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment. Cyclosporine, the active principle in Gengraf®Oral Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. INSTRUCTIONS FOR USE ABBVIE SNUG VEST INSTRUCTIONS FOR USE AbbVie Snug Vest For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Snug Vest.For questions or problems, refer to these Instructions for Use or call support toll free at 1- RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) BLEPHAMIDE ® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile Full Prescribing Information. BOTOX ® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use Full PrescribingInformation.
HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA SAFELY … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 1 INDICATIONS AND USAGE 1.1 Rheumatoid Arthritis RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. GENGRAF ORAL SOLUTION (CYCLOSPORINE ORAL SOLUTION, USP DESCRIPTION Gengraf®Oral Solution (cyclosporine oral solution, USP ) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment. Cyclosporine, the active principle in Gengraf®Oral Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) BLEPHAMIDE ® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile Full Prescribing Information. BOTOX ® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use Full PrescribingInformation.
HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA SAFELY … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 1 INDICATIONS AND USAGE 1.1 Rheumatoid Arthritis RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. GENGRAF ORAL SOLUTION (CYCLOSPORINE ORAL SOLUTION, USP DESCRIPTION Gengraf®Oral Solution (cyclosporine oral solution, USP ) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment. Cyclosporine, the active principle in Gengraf®Oral Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids.MEDICATION GUIDE
MEDICATION GUIDE CREON® (krē ′ŏn) (pancrelipase) Delayed-Release Capsules Read this Medication Guide before you start taking CREON and each time you get a refill.ABBVIE™ PEG
The AbbVie PEG is a percutaneous endoscopic gastrostomy (PEG, or gastric) tube, either 15 FR or 20 FR and 35 cm in length. The kit includes the following (Fig. HIGHLIGHTS OF PRESCRIBING INFORMATION … HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNTHROID® safely and effectively. See full prescribing information INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 3 DOSAGE FORMS AND STRENGTHS Extended-release tablet: 200 mg of dasabuvir (equivalent to 216.2 mg of dasabuvir sodium monohydrate), 8.33 mg of ombitasvir, 50 mg of HIGHLIGHTS OF PRESCRIBING INFORMATION • CO … FULL PRESCRIBING INFORMATION WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs includingsedative hypnotics,
HIGHLIGHTS OF PRESCRIBING INFORMATION •PREGNANCY (4,8.1 Figure 4 5. Hold the syringe upright. With the opposite hand pull the needle cap upward without twisting. 6. Keep the syringe upright. Advance the plunger to expel the air from the syringe. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information. For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. HIGHLIGHTS OF PRESCRIBING INFORMATION • ORGANIC ANION pulmonary embolism). Estrogen and progestin combinations, including the estradiol/norethindrone acetate component of ORIAHNN, HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) You are leaving the RXABBVIE.COM Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA SAFELY … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS …VIEKIRA PAK PRESCRIBING INFORMATIONVIEKIRA PAK ABBVIEVIEKIRA PAK DISCONTINUEDVIEKIRA PAK PATIENT ASSISTANCE PROGRAMVIEKIRA PAK VSVIEKIRA XR
administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information. For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) You are leaving the RXABBVIE.COM Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA SAFELY … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS …VIEKIRA PAK PRESCRIBING INFORMATIONVIEKIRA PAK ABBVIEVIEKIRA PAK DISCONTINUEDVIEKIRA PAK PATIENT ASSISTANCE PROGRAMVIEKIRA PAK VSVIEKIRA XR
administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information. For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. HIGHLIGHTS OF PRESCRIBING INFORMATION … HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNTHROID® safely and effectively. See full prescribing informationMEDICATION GUIDE
MEDICATION GUIDE CREON® (krē ′ŏn) (pancrelipase) Delayed-Release Capsules Read this Medication Guide before you start taking CREON and each time you get a refill. HIGHLIGHTS OF PRESCRIBING INFORMATION •PREGNANCY (4,8.1 Figure 4 5. Hold the syringe upright. With the opposite hand pull the needle cap upward without twisting. 6. Keep the syringe upright. Advance the plunger to expel the air from the syringe. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 3 DOSAGE FORMS AND STRENGTHS Extended-release tablet: 200 mg of dasabuvir (equivalent to 216.2 mg of dasabuvir sodium monohydrate), 8.33 mg of ombitasvir, 50 mg of HIGHLIGHTS OF PRESCRIBING INFORMATION • CO … FULL PRESCRIBING INFORMATION WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs includingsedative hypnotics,
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 2.1 Dosing and Dose Adjustment The recommended starting dose of AndroGel 1.62% is 40.5 mg of testosterone (2 pump actuations or a single 40.5 mg packet) applied GENGRAF ORAL SOLUTION (CYCLOSPORINE ORAL SOLUTION, USP DESCRIPTION Gengraf®Oral Solution (cyclosporine oral solution, USP ) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment. Cyclosporine, the active principle in Gengraf®Oral Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) You are leaving the RXABBVIE.COM Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA SAFELY … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS …VIEKIRA PAK PRESCRIBING INFORMATIONVIEKIRA PAK ABBVIEVIEKIRA PAK DISCONTINUEDVIEKIRA PAK PATIENT ASSISTANCE PROGRAMVIEKIRA PAK VSVIEKIRA XR
administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information. For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. RXABBVIEZEMPLAR (PARICALCITOL) INJECTIONSYNTHROID (LEVOTHYROXINE SODIUM TABLETS, USP) You are leaving the RXABBVIE.COM Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. RCERTAIN INFORMATION THAT IS NOT INTENDED FOR PATIENTS HAS CADD-Legacy ® 1400 Pump. Model 1400. Legacy. Operator’s Manual. This operator’s manual is for clinician use only. Read the entire operator’s manual before HIGHLIGHTS OF PRESCRIBING INFORMATION • INJECTION: 75 … Adverse Drug Reactions SKYRIZI N = 1306 n (%) Placebo N = 300 n (%) Upper respiratory infectionsa 170 (13.0) 29 (9.7) Headacheb 46 (3.5) 6 (2.0) Fatiguec 33 (2.5) 3 (1.0) Injection site reactionsd 19 (1.5) 3 (1.0) Tinea infectionse 15 (1.1) 1 (0.3) aIncludes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORILISSA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION 3 PRS 16 WEEKS … 2.3 Liver or Kidney Transplant Recipients 2.4 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Risk of Hepatitis B Virus Reactivation in PatientsCoinfected with HCV
HIGHLIGHTS OF PRESCRIBING INFORMATION VENCLEXTA SAFELY … Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine, until disease progression or unacceptable toxicity. Refer to Clinical Studies (14.2) and Prescribing Information for azacitidine, decitabine, or HIGHLIGHTS OF PRESCRIBING INFORMATION JUVENILE IDIOPATHIC HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS …VIEKIRA PAK PRESCRIBING INFORMATIONVIEKIRA PAK ABBVIEVIEKIRA PAK DISCONTINUEDVIEKIRA PAK PATIENT ASSISTANCE PROGRAMVIEKIRA PAK VSVIEKIRA XR
administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information. For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. INSTRUCTIONS FOR USE ABBVIE CHEST PACK INSTRUCTIONS FOR USE AbbVie Chest Pack For use with CADD-Legacy® 1400 pump This guide pertains only to the use of the AbbVie Chest Pack. Forquestions
MRI SAFETY INFORMATION MRI Safety Information The AbbVie J (Intestinal Tube 9 FR for PEG 15 and 20 FR / 62918-001, AV062-001)contains a small piece of metal in the tube tip for x-ray visibility of the tube. HIGHLIGHTS OF PRESCRIBING INFORMATION … HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNTHROID® safely and effectively. See full prescribing informationMEDICATION GUIDE
MEDICATION GUIDE CREON® (krē ′ŏn) (pancrelipase) Delayed-Release Capsules Read this Medication Guide before you start taking CREON and each time you get a refill. HIGHLIGHTS OF PRESCRIBING INFORMATION •PREGNANCY (4,8.1 Figure 4 5. Hold the syringe upright. With the opposite hand pull the needle cap upward without twisting. 6. Keep the syringe upright. Advance the plunger to expel the air from the syringe. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 3 DOSAGE FORMS AND STRENGTHS Extended-release tablet: 200 mg of dasabuvir (equivalent to 216.2 mg of dasabuvir sodium monohydrate), 8.33 mg of ombitasvir, 50 mg of HIGHLIGHTS OF PRESCRIBING INFORMATION • CO … FULL PRESCRIBING INFORMATION WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs includingsedative hypnotics,
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … 2.1 Dosing and Dose Adjustment The recommended starting dose of AndroGel 1.62% is 40.5 mg of testosterone (2 pump actuations or a single 40.5 mg packet) applied GENGRAF ORAL SOLUTION (CYCLOSPORINE ORAL SOLUTION, USP DESCRIPTION Gengraf®Oral Solution (cyclosporine oral solution, USP ) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment. Cyclosporine, the active principle in Gengraf®Oral Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. U.S. PRESCRIBING INFORMATION Please click on the links below for detailed AbbVie productinformation.
AndroGel® (testosterone gel) 1% Full Prescribing Information AndroGel® (testosterone gel) 1% Medication Guide AndroGel® (testosterone gel) 1.62% Full Prescribing Information AndroGel® (testosterone gel) 1.62% Medication Guide CREON® (pancrelipase) Delayed-Release Capsules Full PrescribingInformation
CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Chinese CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Korean CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Russian CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Spanish CREON® (pancrelipase) Delayed-Release Capsules Medication Guide Depacon® (valproate sodium injection) DEPAKENE® (valproic acid capsules and oral solution, USP) DEPAKENE® (valproic acid capsules and oral solution, USP) MedicationGuide
Depakote® (divalproex sodium) Delayed-Release Tablets Depakote® (divalproex sodium) Delayed-Release Tablets MedicationGuide
Depakote® ER (divalproex sodium) Extended-Release Tablets Depakote® ER (divalproex sodium) Extended-Release Tablets MedicationGuide
Depakote® Sprinkle Capsules (divalproex sodium delayed-releasecapsules)
Depakote® Sprinkle Capsules (divalproex sodium delayed-release capsules) Medication Guide DUOPA (carbidopa and levodopa) enteral suspension Full Prescribing Information with Medication Guide and Patient Instructions For Use DUOPA (carbidopa and levodopa) enteral suspension Full Prescribing Information with Medication Guide and Patient Instructions For Use -Spanish
DUOPA (carbidopa and levodopa) enteral suspension CADD-Legacy 1400 Pump Operator’s Manual DUOPA: AbbVie Chest Pack Instructions For Use DUOPA: AbbVie Cross Body Pack Instructions For Use DUOPA: AbbVie Hip Pack Instructions For Use DUOPA: AbbVie J Tube Instructions For Use, Including MRI Safety Information Supplement DUOPA: AbbVie Lightweight Vest Instructions For Use DUOPA: AbbVie MRI Safety Information Supplement DUOPA: AbbVie NJ Tube Instructions For Use DUOPA: AbbVie PEG Tube Kit Instructions For Use DUOPA: AbbVie Snug Vest Instructions For Use GENGRAF® Capsules (cyclosporine capsules, USP) Gengraf® Oral Solution (cyclosporine oral solution, USP) HUMIRA® (adalimumab) Full Prescribing Information HUMIRA® (adalimumab) Full Prescribing Information HUMIRA® (adalimumab) Full Prescribing Information - Chinese HUMIRA® (adalimumab) Full Prescribing Information - Spanish HUMIRA® (adalimumab) Medication Guide K-TAB® (potassium chloride extended-release tablets, USP) KALETRA® (lopinavir/ritonavir) Capsules - Full PrescribingInformation
KALETRA® (lopinavir/ritonavir) Tablets and KALETRA® (lopinavir/ritonavir) Oral Solution - Full Prescribing Information KALETRA® (lopinavir/ritonavir) Tablets and KALETRA® (lopinavir/ritonavir) Oral Solution - Medication Guide LUPANETA PACK® (leuprolide acetate for depot suspension and norethindrone acetate tablets) 3.75 mg LUPANETA PACK® (leuprolide acetate for depot suspension and norethindrone acetate tablets) 11.25 mg LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3 Month11.25 mg
LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3 Month11.25 mg - Spanish
LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3.75 mg and 3 Month 11.25 mg LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3.75 mg and 3 Month 11.25 mg - Spanish LUPRON DEPOT® (leuprolide acetate for depot suspension) URO LUPRON DEPOT-PED® (leuprolide acetate for depot suspension) LUPRON DEPOT-PED® (leuprolide acetate for depot suspension) -Spanish
MARINOL® (dronabinol) Capsules Full Prescribing Information MARINOL® (dronabinol) Capsules Patient Information MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Full Prescribing Information MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Full Prescribing Information - Spanish MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral usePatient Information
MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Patient Information - Spanish MIVACRON® Injection (mivacurium chloride) Full PrescribingInformation
Moderiba™ (ribavirin, USP) Tablets Moderiba™ (ribavirin, USP) Tablets NIASPAN® (niacin extended-release tablets) NIMBEX® (cisatracurium besylate) NIMBEX® (cisatracurium besylate) Injection PremierProRx™ Full Prescribing Information NORVIR® Capsules (ritonavir capsules) NORVIR® (ritonavir tablets, oral solution, and oral powder) ORILISSA™ (elagolix) tablets, for oral use, 150 mg and 200 mg, Full Prescribing Information with Medication Guide ORILISSA™ (elagolix) tablets, for oral use, 150 mg and 200 mg, Full Prescribing Information with Medication Guide - Spanish ORILISSA™ (elagolix) tablets, for oral use, 150 mg and 200 mg,Medication Guide
RINVOQ™ (upadacitinib) extended-release tablets, for oral use Full Prescribing Information RINVOQ™ (upadacitinib) extended-release tablets, for oral useMedication Guide
SKYRIZI™ (risankizumab-rzaa) Full Prescribing Information SKYRIZI™ (risankizumab-rzaa) Full Prescribing Information - Spanish SKYRIZI™ (risankizumab-rzaa) Medication Guide SURVANTA® (beractant) intratracheal suspension Full PrescribingInformation
SYNTHROID® (levothyroxine sodium tablets, USP) SYNTHROID® (levothyroxine sodium tablets, USP) SYNTHROID® (levothyroxine sodium tablets, USP) - Spanish TARKA® (trandolapril/verapamil HCI ER) TECHNIVIE® (ombitasvir, paritaprevir, and ritonavir tablets), for oral use Full Prescribing Information and Medication Guide TECHNIVIE® (ombitasvir, paritaprevir, and ritonavir tablets), for oral use Full Prescribing Information and Medication Guide TECHNIVIE® (ombitasvir, paritaprevir, and ritonavir tablets), for oral use Medication Guide TRICOR® (fenofibrate) tablets TRIDIONE® (trimethadione) Tablets TRILIPIX® (fenofibric acid) delayed-release capsules - Full Prescribing Information ULTANE® (sevoflurane) ULTANE® (sevoflurane) - NOVAPLUS™ VENCLEXTA® (venetoclax tablets) for oral use Full PrescribingInformation
VENCLEXTA® (venetoclax tablets) for oral use Full PrescribingInformation
VENCLEXTA® (venetoclax tablets) for oral use Full Prescribing Information - Spanish VENCLEXTA® (venetoclax tablets) for oral use Medication Guide VICODIN® (hydrocodone bitartrate and acetaminophen tablets, USP) 5 mg/300 mg; VICODIN ES® (hydrocodone bitartrate and acetaminophen tablets, USP) 7.5 mg/300 mg; VICODIN HP® (hydrocodone bitartrate and acetaminophen tablets, USP) 10 mg/300 mg VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Full Prescribing Information and Medication Guide VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Full Prescribing Information and Medication Guide VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Medication Guide VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use Medication Guide VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use Full Prescribing Information and Medication Guide VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use Full Prescribing Information and Medication Guide ZEMPLAR® (paricalcitol) Capsules ZEMPLAR® (paricalcitol) Injection ZEMPLAR® (paricalcitol) Injection YOU ARE ENCOURAGED TO REPORT NEGATIVE SIDE EFFECTS OF PRESCRIPTION DRUGS TO THE FDA. VISIT WWW.FDA.GOV/MEDWATCH , OR CALL 1-800-FDA-1088(1-800-332-1088).
If you cannot afford yourmedication, contact
www.pparx.org
for assistance.
For Healthcare Professionals seeking medical information for an AbbVie product, visit www.abbviemedinfo.com . * © 2013, 2016, 2019 AbbVie Inc.* Contact Us
* Privacy policy
* Terms of use
×
You are leaving the RXABBVIE.COM Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.OK Cancel
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0